Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 5/20 | 0.31 |
| ▸ | TP53 | P04637 | 4/20 | 0.31 |
| ▸ | CLK1 | P49759 | 1/20 | 0.31 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1343289 | 0.92 | LMNA (0.33) | TP53CLK1 | |
| SCHEMBL1341809 | 0.92 | GAA (0.32) | MAPTCLK1 | |
| SCHEMBL1342230 | 0.92 | ALDH1A1 (0.34) | MAPTTP53CLK1 | |
| SCHEMBL1340502 | 0.91 | MAPT (0.37) | MAPT | |
| SCHEMBL1341051 | 0.91 | MAPT (0.32) | TDP1MAPTTP53 | |
| SCHEMBL1343734 | 0.90 | CSNK1D (0.33) | — | |
| SCHEMBL1342745 | 0.90 | MAPT (0.32) | TDP1MAPTTP53ABCC1 | |
| SCHEMBL1340632 | 0.89 | CCNE1 (0.30) | — | |
| SCHEMBL1342119 | 0.88 | CLK1 (0.37) | TDP1MAPTTP53CLK1ABCC1 | |
| SCHEMBL1342109 | 0.88 | CCNE1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2471533-A1 | Aryl carbonyl derivatives as therapeutic agents | Novo Nordisk A/S (DK) | 2012-07-04 | — | — | EP | disclosed |
| US-20110301158-A1 | ARYL CARBONYL DERIVATIVES AS THERAPEUTIC AGENTS | NOVO NORDISK A/S (DK) | 2011-12-08 | — | — | US | disclosed |
| US-8063081-B2 | N-(2-Phenoxyphenyl)-N'-(thiazol-2-yl)urea; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase | NOVO NORDISK A/S (DK) | 2011-11-22 | — | — | US | disclosed |
| US-7897628-B2 | {2-[3-(4-Methyl-2-[2-methypropoxy]phenyl)-ureido]-thiazol-4-yl}-acetic acid ethyl ester; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase | NOVO NORDISK A/S (DK) | 2011-03-01 | — | — | US | disclosed |
| US-7384967-B2 | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2008-06-10 | — | — | US | disclosed |
| US-20080119454-A1 | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2008-05-22 | — | — | US | disclosed |
| US-20080119455-A1 | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2008-05-22 | — | — | US | disclosed |
| US-20040122235-A1 | Aryl carbonyl derivatives as therapeutic agents | VTV THERAPEUTICS LLC | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301158-A1 | ARYL CARBONYL DERIVATIVES AS THERAPEUTIC AGENTS | GCK, GCKR, PDK2 | TDP1 3398/4885MAPT 2678/4885TP53 2961/4885 |
| US-20080119455-A1 | Aryl carbonyl derivatives as therapeutic agents | GCK, GCKR, PDK2 | TDP1 3398/4885MAPT 2678/4885TP53 2961/4885 |
| US-20040122235-A1 | Aryl carbonyl derivatives as therapeutic agents | GCK, GCKR, PDK2 | TDP1 3398/4885MAPT 2678/4885TP53 2961/4885 |
| US-20080119454-A1 | Aryl carbonyl derivatives as therapeutic agents | GCK, GCKR, PDK2 | TDP1 3398/4885MAPT 2678/4885TP53 2961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.